Skip to main content
梓橦宫 logo

梓橦宫 — Investor Relations & Filings

Ticker · 920566 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 625 across all filing types
Latest filing 2023-08-31 Investor Presentation
Country CN China
Listing Beijing Stock Exchange 920566

About 梓橦宫

http://www.zitonggong.com/

Zitonggong specializes in the research, development, and production of specialized therapeutic agents. Established with a heritage dating back to 1780, the company holds a recognized heritage brand designation. Its primary product portfolio centers on neurological and cerebrovascular health, featuring Oxiracetam in various dosage forms for treating cognitive dysfunction and brain injuries. The company also develops treatments for digestive health, including Compound Aloe Capsules, and produces artificial Oriental Bezoar. Operations are centered on integrating traditional medicinal knowledge with modern chemical synthesis and manufacturing standards. The company maintains a focus on clinical efficacy and technological advancement in the fields of neurology and gastroenterology.

Recent filings

Filing Released Lang Actions
2023年半年度报告业绩说明会预告公告
Investor Presentation Classification · 90% confidence The document is a short announcement (1002 characters) about a scheduled performance explanation meeting related to the company's 2023 half-year report. It references the half-year report but does not contain actual financial data or the report itself. The document invites investors to participate in a webcast meeting to discuss the half-year results. This fits the description of an Investor Presentation (IP) or a Call Transcript (CT) if it were the transcript, but since it is a notice of an upcoming meeting, it is best classified as an Investor Presentation (IP) announcement. However, since it is only a notice of the meeting and not the presentation itself, and it is not a report publication announcement, the closest fitting category is Investor Presentation (IP) because it is about a detailed presentation for investors focusing on financials and strategy. Confidence is high due to clear references to the half-year report and the meeting details for investors.
2023-08-31 Chinese
关于获得马甲子胶囊药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the approval of a clinical trial for a drug (Majiazi Capsule) by the National Medical Products Administration. It details the approval notice, the clinical trial's basic information, and the company's risk warning about the drug development process. The document is short (813 characters) and serves as a regulatory announcement about a clinical trial approval, not a financial report or detailed management discussion. It does not contain financial data, earnings, or management changes. It is a regulatory announcement about a specific event related to drug approval, fitting best under Regulatory Filings (RNS).
2023-08-28 Chinese
关于获得马甲子胶囊药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the approval of a clinical trial for a drug called Majiazi Capsule by the National Medical Products Administration. It details the approval notice, the clinical trial's basic information, and the company's risk warning about the drug development process. The document is short (813 characters) and serves as a regulatory announcement about a clinical trial approval, not a financial report or detailed management discussion. It does not contain financial data, earnings, or management changes. It is a regulatory announcement about a significant event related to the company's operations. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-08-28 Chinese
持股5%以上股东减持股份结果公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the reduction of shareholding by a shareholder holding more than 5% of the company's shares. It details the shareholder's name, shareholding before and after reduction, the method and period of reduction, and confirms whether the reduction aligns with previously disclosed plans. This fits the definition of a Major Shareholding Notification, specifically reporting a change in significant share ownership levels crossing thresholds. The document is not a full financial report, earnings release, or regulatory filing but a specific notification about shareholding changes.
2023-08-27 Chinese
上海天璇律师事务所关于四川梓橦宫药业股份有限公司2023年第四次临时股东大会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the procedural legality of a company's 2023 fourth extraordinary general meeting of shareholders. It details the convening, attendance, voting procedures, and results of the shareholders' meeting, confirming compliance with relevant laws and company articles. It does not contain financial statements, earnings data, or management discussion, nor is it a report publication announcement. The document is focused on legal validation of the shareholders' meeting process and voting results, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 3480 characters, which is consistent with a detailed legal opinion on voting results rather than a full annual or interim report.
2023-08-27 Chinese
监事会关于2023年股权激励计划相关事项的核查意见
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the supervisory board of Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the verification opinion on the 2023 equity incentive plan. It discusses the approval and adjustments related to the equity incentive plan, including the grant date, pricing, number of recipients, and compliance with relevant laws and regulations. The content focuses on corporate governance and management decisions related to stock incentives rather than financial results, audit opinions, or shareholder meeting materials. It is not a full annual or interim report, nor is it a call transcript or earnings release. It is also not a proxy solicitation or voting result announcement. The document is a regulatory announcement about management and governance matters related to equity incentives, which fits best under Regulatory Filings (RNS) as it does not fit other more specific categories and is a formal compliance disclosure.
2023-08-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.